Skip to the content
Please enable JavaScript in your browser to complete this form.
(
*
) Mandatory field
Title
*
[Please select]
Mr
Ms
Dr
Professor
First name
*
Last name
*
Place of Practice
*
Email Address
*
Member of
*
[Please select]
Hong Kong College of Paediatricians
The Hong Kong College of Pathologists
Hong Kong College of Physicians
Hong Kong College of Radiologists
Others - Hong Kong
Others - Macau
Member of_others - Hong Kong
*
Member of_others - Macau
*
Special Dietary Request
*
[Please select]
None
Vegetarian
Others
Special Dietary Request_others
*
We would like to invite you to participate in a short pre-meeting survey. This survey will help us ensure that the symposium covers relevant topics aligned with your expertise and interests. Thank you for your commitment, and we look forward to receiving your survey responses.
1. When selecting first-line treatment for LR-MDS patients, which factors most heavily influence your decision-making, and how do you prioritise these factors?
(Select all that apply)
1. When selecting first-line treatment for LR-MDS patients, which factors most heavily influence your decision-making, and how do you prioritise these factors?
Cytogenetics and mutation status
Patient age and comorbidities
Risk of adverse events and quality of life
Patient preference and treatment goals
All of the above, equally
decision-making, the agree
2. How often do you adjust treatment plans for LR-MDS patients based on adverse event profiles, and what strategies do you typically employ to manage these events while maintaining treatment efficacy?
2. How often do you adjust treatment plans for LR-MDS patients based on adverse event profiles, and what strategies do you typically employ to manage these events while maintaining treatment efficacy?
Frequently, using dose modifications
Occasionally, switching to alternative therapies
Rarely, managing side effects without altering treatment
Never, as I stick to the initial treatment plan unless disease progression occurs
3. In your experience, how well do current treatment guidelines align with the real-world challenges you face in treating LR-MDS patients, particularly in terms of patient selection, treatment sequencing, and management of adverse events?
3. In your experience, how well do current treatment guidelines align with the real-world challenges you face in treating LR-MDS patients, particularly in terms of patient selection, treatment sequencing, and management of adverse events?
Very well – guidelines provide a clear roadmap
Fairly well – I sometimes deviate based on patient-specific factors
Occasionally – I often face challenges that require deviation from guidelines
Poorly – real-world scenarios rarely align with guidelines
Disclaimer: All data collected will be used for meeting use only.
I am a healthcare professional.*
*
I am a healthcare professional.
*
I agree the meeting organizer to collect my personal data for this meeting use.*
*
I agree the meeting organizer to collect my personal data for this meeting use.
*
It is important that you take the time to read through and understand the
Terms of Use
and
Privacy Policy
.
Submit